A peer-reviewed study published in the International Journal of Obesity evaluated NOVI Health's NOVI Optimum Plus program, integrating GLP-1 medications with digital coaching, in 708 multi-ethnic Asian adults.1
Participants achieved ~12.7% mean weight loss at 12 months and ~14.7% at 18 months, matching gold-standard clinical trial results like STEP 1 (15%) and exceeding typical real-world outcomes (~9% at 12 months).1
Active engagers with the digital platform saw 2.0-2.2% additional weight loss (15% greater relative loss), ~0.72 kg/m² greater BMI reduction, and up to 2.9 mmHg more systolic BP reduction compared to low engagers.1
Broader benefits included ~12 mmHg systolic BP decrease, ~9% body fat reduction, waist-to-hip ratio improvement from 0.83 to 0.80, and ~0.6% HbA1c decline.1
Ethnic variations:
East Asians and those with hyperglycemia had lower weight loss; Europeans and mixed-ethnicity had greater reductions. Dr. Sue-Anne Toh emphasized tailored approaches for Asia's diverse profiles.1
Study conducted with Saw Swee Hock School of Public Health at National University of Singapore; announced April 22, 2026.1
Sources:
1. https://www.prnewswire.com/apac/news-releases/novi-healths-hybrid-care-model-closes-gap-between-clinical-trials-and-real-world-glp-1-outcomes-302748527.html